- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02827370
CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer
CAREFOR Study: Precision Nutrition Caloric Restriction for Oncology Research: Precision Medicine Driving Precision Nutrition During Neoadjuvant Chemotherapy for Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary objective:
I To determine if dietary alternations designed to downregulate the dominate molecular drivers of an individuals' breast cancer will enhance the effect of neoadjuvant chemotherapy and allow for an increase in the pathologic complete response rate.
Secondary objectives
I) Investigator measurable changes to molecular and patient characteristics from precision nutrition to determine a metric for evaluation this treatment in future studies.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pathologically proven invasive breast cancer
- Planned neoadjuvant chemotherapy determined by the judgment of the medical oncologist
- The patient must be female
- Age ≥ 18
- Non-metastatic and non-inflammatory breast cancer
- History/physical examination, including breast exam and documentation of weight and Karnofsky Performance Status of 80-100% for at least 60 days prior to study entry.
- Women of childbearing potential must be non-pregnant and non-lactating and willing to use medically acceptable form of contraception during chemotherapy
- Patient must capable of and provide study specific informed consent prior to study entry
- BMI ≥21
- Weight ≥120lbs
- No prior history of non-breast malignancies in the past 1 year unless it was a non- melanomatous skin lesion or carcinoma in situ of the cervix.
- Patient must not have Acquired Immune Deficiency Syndrome (AIDS) or HIV positive based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS or HIV from this protocol is necessary because anti-retrovirals may alter patient metabolism.
- Patient may not have any active Gastrointestinal/Malabsorption disorder at the discretion of the Principal Investigator which may include:
- Chronic Pancreatitis
- Chronic Diarrhea or Vomiting
- Active Eating Disorder
- No history of or current active drug/alcohol dependence.
- No patients with decisional impairment.
Exclusion Criteria:
- Patient is male.
- Age <18 years
- Clinical stage IV cancer
- Inflammatory breast cancer (T4d)
- Women of childbearing potential with a positive serum beta hCG.
- Decision impaired patients.
- BMI < 21
- Weight < 120lbs
- Weight loss ≥10% in the last 3 mos
- Prior invasive non-breast malignancy (except non-melanomatous skin cancer, carcinoma in situ of the cervix) unless disease free for a minimum of 1 year prior to registration
- Non-epithelial breast malignancies such as sarcoma or lymphoma
Active Gastrointestinal/Malabsorption disorder at the discretion of the Principal -Investigator which may include:
- Chronic Diarrhea or Vomiting
- Active Eating Disorder
- Active drug/alcohol dependence or abuse history.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Precision Nutrition (dietary intervention)
During chemotherapy, patients will receive dietary counseling based on the molecular pathways driving their specific breast cancers found through genetic testing.
Nutritional recommendations will seek to down-regulate the dominant molecular drivers of an individual's breast cancer while they are receiving standard chemotherapy as outlined by their treating medical oncologist.
|
Receive dietary counseling
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic complete response assessed in tissue
Time Frame: At time of definitive breast surgery
|
The portion of patients who adhere to the diet restriction will be computed along with a 95% exact confidence.
An exact binomial test (with a onesided alpha of 0.05) will also be used to test whether adherence is greater than 60%.
|
At time of definitive breast surgery
|
Incidence of adverse events evaluated by CTCAE version 4.0
Time Frame: Up to 24 months
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of study participants who receive the dietary intervention to the historical controls
Time Frame: Up to 24 months
|
Will be compared to historical controls.
Will be based on logistic regression, which will control for patient characteristics and clinical factors.
The study has 81% power to detect an odds ratio of about 0.25 using a 2-sided alpha of 0.05
|
Up to 24 months
|
Weight changes
Time Frame: Up to 24 months
|
Will be assessed by modeling body mass index as a function of time via mixed-effects regression.
|
Up to 24 months
|
Change in insulin
Time Frame: Up to 24 months
|
Will be assessed as a function of time via mixed-effects regression.
|
Up to 24 months
|
Change in serum
Time Frame: Up to 24 months
|
Will be assessed as a function of time via mixed-effects regression.
|
Up to 24 months
|
Distant metastases
Time Frame: Up to 24 months
|
Will be analyzed via the Kaplan-Meier method and the logrank test.
|
Up to 24 months
|
Progression-free survival
Time Frame: Up to 24 months
|
Kaplan-Meier curves will be generated and a log-rank value will be calculated.
|
Up to 24 months
|
Overall survival
Time Frame: Up to 24 months
|
Will be analyzed with the Kaplan-Meier method and Cox proportional hazards regression.
|
Up to 24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nicole Simone, MD, Thomas Jefferson University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16D.067
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Carcinoma
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedInvasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | Lobular Breast Carcinoma | Postmenopausal | Ductal Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in SituUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Cianna Medical, Inc.TerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma and other conditionsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingCancer Survivor | Invasive Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
Ohio State University Comprehensive Cancer CenterWithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ
-
Case Comprehensive Cancer CenterWithdrawnStage I Breast Cancer | HER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage IA Breast Cancer | Stage IB Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Lobular Breast Carcinoma | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); California Breast Cancer Research ProgramCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Lobular Breast Carcinoma in SituUnited States
Clinical Trials on Behavioral Dietary Intervention
-
Brown UniversityNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Brown UniversityNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Rush University Medical CenterUniversity of Chicago; National Institute on Aging (NIA); Advocate Hospital SystemRecruitingStroke | Dementia | Alzheimer Disease | Dementia, Vascular | Cognitive DeclineUnited States
-
Case Comprehensive Cancer CenterCompletedEndometrial Cancer | Weight ChangesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Josephine Ford Cancer CenterNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedEndometrial CancerUnited States
-
Virginia Polytechnic Institute and State UniversityNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Not yet recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedStage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States